NCT06334705

EGEA4 THE 30 YEAR FOLLOW UP OF THE EGEA STUDY

Recruiting now NA Last updated 19 September 2025

What this trial tests

NA trial testing blood test, food collection, hair collection, calcium scan, etc. in Healthy Volunteer EGEA4 Cohort in 1,000 participants. Currently enrolling.

Timeline

15 February 2024

Primary endpoint
15 February 2027

15 February 2028

Quick facts

Lead sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	1,000
Start date	15 February 2024
Primary completion	15 February 2027
Estimated completion	15 February 2028
Sites	5 locations across France

Drugs / interventions tested

• blood test, food collection, hair collection, calcium scan, etc.

Conditions studied

• Healthy Volunteer EGEA4 Cohort — all drugs for Healthy Volunteer EGEA4 Cohort →

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France — full company profile →

Who can join

18 and older, any sex, with Healthy Volunteer EGEA4 Cohort. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiovascular (CV) diseases affect 523 million people worldwide, and are the leading cause of death, accounting for over 18 million deaths (around 30% of all deaths) every year. CV diseases account for around 45% of all deaths in Europe, or around 140,000 deaths a year in France. Asthma is one of the main non-communicable diseases, with a significant societal and individual burden, particularly in subjects suffering from severe asthma. The prevalence of asthma worldwide has risen rapidly over the past five decades, and now affects 272 million people worldwide, representing a prevalence of around 3.6%.

Asthma is often associated with multimorbidity. Allergic rhinitis, chronic sinusitis, sleep apnea syndrome, gastro-oesophageal reflux disease, obesity and hormonal disorders are among the most common conditions associated with asthma. More recently, other chronic conditions linked to asthma have been suggested, including CV diseases.

Although data from the literature in recent years suggest that asthma is associated with an increased risk of major CV events, the underlying mechanisms remain poorly understood. In particular, it is not known whether asthma and CV disease share common etiological processes, such as anthropometric parameters, lifestyle, social, environmental and/or genetic factors, or whether CV disease is a direct consequence of certain features of asthma, such as systemic inflammation or asthma treatments.

Our study is based on the hypothesis that the risk of CV events is increased in patients with asthma, which is supported by a growing body of scientific data.However, it remains to be determined to what extent this increased risk is a consequence of asthma or is linked to shared risk factors between asthma and CV health.

We hypothesize that asthma, and more specifically adult and moderate-to-severe asthma, are associated with early markers of CV risk. Furthermore, by providing a better understanding of the mechanisms involved in this association, we hypothesize that EGEA\_30years may help to disentangle and prioritize actionable levers of life-threatening cardiovascular comorbidities in asthma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.